Enhancing CAR T cell therapy for brain tumors
Official title: Improving CAR T cell therapy for brain tumors using immune competent models
Funded at Children's Research Institute · NIH-11001478 · Data updated 2026-11-12
This study is looking at ways to make CAR T cell therapy better for people with high grade gliomas, a tough type of brain tumor, by tweaking the T cells to help them fight the tumor more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Research Institute NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | January 1, 2021 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $215,029 |
| NIH project number | 5R00CA256262-05 |
| Project ID | NIH-11001478 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with high grade gliomas who may benefit from advanced CAR T cell therapies.
✕Less likely to help
Patients with other types of brain tumors or those who are not eligible for CAR T cell therapy may not receive benefits from this research.
What this research studies
This research focuses on improving CAR T cell therapy specifically for high grade gliomas, a type of brain tumor with poor treatment outcomes. The approach involves engineering T cells to better target and attack tumor cells by optimizing their design and genetic modifications. The effectiveness of these modified T cells will be tested in immune competent mouse models that closely resemble human brain tumor conditions. By addressing challenges such as tumor microenvironment and T cell exhaustion, the research aims to enhance the immune response against these tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with high grade gliomas, potentially improving survival rates and quality of life.
How similar studies have gone: While CAR T cell therapy has shown promise in other cancers, its application in high grade gliomas is still being explored, making this research both innovative and necessary.
Where this research is happening
-
Children's Research Institute
Washington, United States Active
Researchers
- Principal investigator: Haydar, Dalia — Children's Research Institute
- Study coordinator: Haydar, Dalia
Related research
Other NIH-funded projects on the same topics.
-
Implantable scaffolds to make CAR‑T therapy stronger and cheaper for brain tumors
This project aims to use a biocompatible implant placed at the tumor site to help CAR‑T immune cells reach and kill glioblastoma cells while reducing the need for repeated, costly infusions.
-
Developing new scaffolds to improve CAR-T cell therapy for brain tumors
This study is looking at a new way to make CAR-T cell therapy work better for people with glioblastoma, a tough brain tumor, by using special scaffolds to help deliver the treatment right to the tumor, so patients can get more effective care.
-
Improving CAR-T cell therapy for brain tumors using focused ultrasound
This study is looking at how using focused ultrasound can help CAR-T cell therapy work better for people with glioblastoma, a type of brain tumor, by making it easier for the treatment to reach and attack the tumor cells in the brain.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.